{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2338"},{"groupId":"OG001","value":"1915"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2338"},{"groupId":"OG001","value":"1915"}],"units":"Participants"}],"description":"Participants diagnosed with NDMM and R/RMM were determined at the start of the study.","groups":[{"description":"Participants newly diagnosed with MM within 3 months from initiation of treatment were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).","id":"OG000","title":"NDMM"},{"description":"Participants diagnosed with RRMM who previously received 1 to 3 prior lines of therapy were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).","id":"OG001","title":"RRMM"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Enrolled Population included all participants who signed the inform consent form.","reportingStatus":"POSTED","timeFrame":"At Baseline","title":"Number of Participants Diagnosed With Newly Diagnosed Multiple Myeloma (NDMM) and Relapsed/Refractory Multiple Myeloma (R/RMM)","type":"PRIMARY","unitOfMeasure":"Participants"}